News | July 31, 2014

Radiation Exposure Concerns, Increased Precision Driving Growth of Corindus Vascular Robotics

Robotic-assisted coronary angioplasties a solution today for hospitals across the country

 Corindus Vascular Robotics CorPath Installations Robotic Systems Cath Lab

July 31, 2014 — As attention increases on the effects of radiation exposure among interventional cardiologists[1], Corindus Vascular Robotics announced the recent installations of its CorPath System at five facilities: UH Case Medical Center, Cleveland, Ohio; Virginia Commonwealth University Medical Center, Richmond, Va.; Miami Cardiac and Vascular Institute, Miami; the second system in Michigan; and first system in North Carolina. In addition, Corindus announced that customers used the CorPath System in a record number of cases in the quarter ending June 2014, the third straight quarter of record-setting utilization. The consistent increase in utilization demonstrates that customers continue to make CorPath the standard of care for PCI.

Corindus’ CorPath System is the first U.S. Food and Drug Administration (FDA)-cleared medical device to bring robotic-assisted precision and accuracy to coronary angioplasty procedures. During a CorPath Robotic Angioplasty procedure, the interventional cardiologist sits in the radiation shielded interventional cockpit, and advances stents and guidewires with millimeter-by-millimeter precision. Robotic angioplasty may improve stent placement, which can reduce repeat procedures. The CorPath System also reduces physician radiation exposure during procedures by 95 percent[2].

“We use the CorPath System on a daily basis at our facility.  We even use the CorPath System as a tool with appropriate complex PCI cases, and continue to see and feel the benefits of robotic precision, along with radiation protection for the physician,” said Daniel Simon, M.D., director, Harrington Heart & Vascular Institute, UH Case Medical Center.

“The threat of radiation exposure and musculoskeletal disorders for interventional cardiologists is poised to become a pivotal industry issue as emerging studies continue to point to a real need for protecting clinicians in the cath lab,” said David Handler, President and CEO of Corindus Vascular Robotics. “We continue to meet with hospital executives who understand the potential cost and risk that radiation poses to their staff, and who see the CorPath System as a way to not only benefit patients, but their physicians as well.”

Corindus has seen the number of customer installs grow across the country, and several customers have recently added second systems to their facility to provide Robotic Angioplasty for more patients and physicians.

Corindus recently exhibited at the Society for Cardiovascular Angiography and Interventions (SCAI) 2014 annual scientific session, where more than 60 physicians attended a breakfast symposium sponsored by Corindus. Five current users spoke about their experience with CorPath and the benefits they derive from the implementation of robotic angioplasty.

For more information, visit www.corindus.com.

References:

1. Wood, Shelley. “Climbing Head and Neck Tumor Count in Interventional Cardiologists Prompts Calls for More Study,” MedScape.com, 23 April 2014, http://www.medscape.com/viewarticle/824022

2. Weisz, G. et al. Safety and Feasibility of Robotic Percutaneous Coronary Intervention: PRECISE (Percutaneous Robotically-Enhanced Coronary Intervention) Study. J Am Coll Cardiol. 2013;61(15):1596-1600.

 

 

 

Related Content

Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Overlay Init